Qiming Venture Partners Weekly | Portfolio Companies Funding and Updates Vol. 29, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
启明创投
@author-1788515151757110
启明创投致力于成为中国优秀技术创业者们的首选投资机构
345 articles
Articles
Rongzi China's Zhu Shan and Qiming Venture Partners' Duane Kuang on AI as the Biggest Paradigm Shift and the Next Generation of Classic Investment Cases
Despite the fierce competition in tech today, many niche segments remain underexplored. The AI space will give rise to ecosystem players on the scale of Xiaomi, creating new opportunities for both industry giants and startups.
Dialogue | Qiming Venture Partners' Alex Zhou with Tashi Zhihang's Yilun Chen and Yuanli Lingji's Tang Wenbin: Macro Consensus and Micro Divergence on Embodied Artificial Intelligence
Continuing to explore general-purpose robots, the ultimate goal of AGI
Dialogue | William Hu and Insilico Medicine's Ren Feng on How AI Is Driving Next-Generation Drug Discovery
For AI drug discovery companies, it's not enough to possess proprietary core technologies — they must also embed themselves deeply into the practical scenarios of pharmaceutical R&D, driving those technologies toward real-world implementation and commercial translation.
Qiming Venture Partners' Portfolio Company WeRide Kicks Off 24/7 Stress Testing in Beijing
WeRide is among the first autonomous driving companies approved to conduct nighttime road tests in Beijing, marking a critical step toward building a "7×24" autonomous driving service network in the city and laying a solid foundation for truly round-the-clock autonomous mobility services.
Minghui Pharmaceutical Raises $131M in Pre-IPO Round Co-Led by Qiming Venture Partners
Minghui Pharmaceutical is a late-stage biopharmaceutical company focused on oncology and autoimmune diseases.
Qiming Venture Partners Portfolio Companies Shine at 2025 World Artificial Intelligence Conference
As one of the most influential industry events in the global artificial intelligence sector, the 2025 World Artificial Intelligence Conference took "Intelligent Era: Shared Responsibility for Our Planet" as its theme, continuing to serve its important roles as a "technology weathervane, application showcase, industry accelerator, and governance forum" — comprehensively presenting the latest developments in cutting-edge AI technology, industrial trends, and global governance practices.
Zenitar Raises Nearly 400 Million Yuan in B+ Round Led by Qiming Venture Partners
Zenitar is a structure-based biology and AI-driven innovative drug R&D company, focused on unmet clinical needs in major therapeutic areas including oncology, autoimmune diseases, inflammation, and neurological disorders. The company is dedicated to discovering, developing, and commercializing first-in-class and best-in-class innovative medicines.
Qiming Weekly | Qiming Venture Partners Portfolio Companies: Funding and Updates Vol. 28, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Evolutionary Tide Raises Hundreds of Millions of Yuan in Pre-A Round, Qiming Venture Partners Co-Leads
Emergent Tide is built on original research from the Tsinghua University School of Medicine team in the field of humoral immunity, developing novel therapeutics for inflammatory and autoimmune diseases against a first-in-class global target, addressing core challenges in the field and significant unmet clinical needs.